Our top pick for
Ebix Inc is a software-application business based in the US. Ebix shares (EBIX) are listed on the NASDAQ and all prices are listed in US Dollars. Ebix employs 9,802 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$30.39|
|52-week range||$17.71 - $62.42|
|50-day moving average||$27.90|
|200-day moving average||$30.05|
|Wall St. target price||$57.75|
|Dividend yield||$0.3 (1.07%)|
|Earnings per share (TTM)||$2.66|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||7.65%|
|1 month (2021-09-17)||9.47%|
|3 months (2021-07-16)||4.08%|
|6 months (2021-04-16)||4.61%|
|1 year (2020-10-16)||45.55%|
|2 years (2019-10-16)||-21.61%|
|3 years (2018-10-16)||62.56|
|5 years (2016-10-14)||56.6|
Valuing Ebix stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ebix's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ebix's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 11x. In other words, Ebix shares trade at around 11x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Ebix's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.16. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Ebix's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Ebix's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $139.2 million.
The EBITDA is a measure of a Ebix's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$912.8 million|
|Operating margin TTM||13.64%|
|Gross profit TTM||$282.3 million|
|Return on assets TTM||5.08%|
|Return on equity TTM||12.17%|
|Market capitalisation||$873.5 million|
TTM: trailing 12 months
There are currently 3.5 million Ebix shares held short by investors – that's known as Ebix's "short interest". This figure is 1.4% down from 3.5 million last month.
There are a few different ways that this level of interest in shorting Ebix shares can be evaluated.
Ebix's "short interest ratio" (SIR) is the quantity of Ebix shares currently shorted divided by the average quantity of Ebix shares traded daily (recently around 128126.25553914). Ebix's SIR currently stands at 27.08. In other words for every 100,000 Ebix shares traded daily on the market, roughly 27080 shares are currently held short.
However Ebix's short interest can also be evaluated against the total number of Ebix shares, or, against the total number of tradable Ebix shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ebix's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Ebix shares in existence, roughly 110 shares are currently held short) or 0.1468% of the tradable shares (for every 100,000 tradable Ebix shares, roughly 147 shares are currently held short).
A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Ebix.
Find out more about how you can short Ebix stock.
Dividend payout ratio: 10.75% of net profits
Recently Ebix has paid out, on average, around 10.75% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.06% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Ebix shareholders could enjoy a 1.06% return on their shares, in the form of dividend payments. In Ebix's case, that would currently equate to about $0.3 per share.
While Ebix's payout ratio might seem low, this can signify that Ebix is investing more in its future growth.
Ebix's most recent dividend payout was on 14 September 2021. The latest dividend was paid out to all shareholders who bought their shares by 1 September 2021 (the "ex-dividend date").
Ebix's shares were split on a 3:1 basis on 31 July 2016. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Ebix shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Ebix shares which in turn could have impacted Ebix's share price.
Over the last 12 months, Ebix's shares have ranged in value from as little as $17.7135 up to $62.4213. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ebix's is 2.672. This would suggest that Ebix's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Ebix, Inc. , together with its subsidiaries, provides on-demand software and e-commerce services and solutions to insurance, financial, healthcare, and e-learning industries in the United States and internationally. It develops and deploys insurance and reinsurance exchanges; provides Software-as-a-Service (SaaS) enterprise solutions in the area of customer relationship management, and front-end and back-end systems; and offers outsourced administrative and risk compliance solutions. The company operates P&C exchanges primarily in Australia, New Zealand, the United Kingdom, and the United States, which facilitates the exchange of insurance data between brokers and insurance carriers with a focus on the areas of personal and commercial lines. Its exchange related products and services include travel exchanges and money transfer services; foreign exchange and outward remittance services; payment services; gift cards for consumers that can be redeemed at various merchants; and technology services for various providers in the areas of lending, wealth and asset management, and travel. The company's insurance exchanges related products and services include SaaS platform and related services; licensing of software; and professional services comprising setting up, customization, training, or consulting. Its risk compliance services cover and certificates of insurance creation and tracking; consulting services comprising project management and development; and business process outsourcing services, including domain intensive project management, system consulting services, and claims adjudication/settlement services.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.